CLNN Insider Trading
Insider Ownership Percentage: 35.30%
Insider Buying (Last 12 Months): $216,664.50
Insider Selling (Last 12 Months): $3,146,492.30
Clene Share Price & Price History
Current Price: $4.27
Price Change: ▲ Price Increase of +0.23 (5.69%)
As of 02/3/2026 05:00 PM ET
Clene Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/2/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 3,800 | $4.04 | $15,352.00 | 555,559 | |
| 1/30/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 5,686 | $4.13 | $23,483.18 | 559,359 | |
| 1/29/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 15,284 | $4.32 | $66,026.88 | 565,045 | |
| 1/28/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 8,717 | $4.91 | $42,800.47 | 580,329 | |
| 1/27/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 4,139 | $5.08 | $21,026.12 | 589,046 | |
| 1/26/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 6,418 | $5.02 | $32,218.36 | 593,185 | |
| 1/23/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 5,556 | $5.27 | $29,280.12 | 599,603 | |
| 1/22/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 12,665 | $5.32 | $67,377.80 | 605,159 | |
| 1/21/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 12,119 | $5.05 | $61,200.95 | 617,824 | |
| 1/20/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 12,432 | $4.80 | $59,673.60 | 629,943 | |
| 1/16/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 7,923 | $5.13 | $40,644.99 | 642,375 | |
| 1/15/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 12,563 | $5.10 | $64,071.30 | 650,298 | |
| 1/14/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 19,621 | $5.12 | $100,459.52 | 662,861 | |
| 1/13/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 26,105 | $4.89 | $127,653.45 | 682,482 | |
| 1/13/2026 | David J Matlin | Director | Buy | 33,333 | $6.50 | $216,664.50 | 477,824 | |
| 1/12/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 32,705 | $5.50 | $179,877.50 | 708,587 | |
| 1/9/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 9,075 | $6.27 | $56,900.25 | 741,292 | |
| 1/8/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 3,195 | $6.09 | $19,457.55 | 750,367 | |
| 1/7/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 3,938 | $6.29 | $24,770.02 | 753,562 | |
| 1/6/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 3,111 | $6.04 | $18,790.44 | 757,500 | |
| 1/5/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 5,869 | $5.87 | $34,451.03 | 760,611 | |
| 1/2/2026 | Chidozie Ugwumba | Major Shareholder | Sell | 4,015 | $5.73 | $23,005.95 | 766,480 | |
| 12/31/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 13,095 | $5.81 | $76,081.95 | 770,495 | |
| 12/30/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 4,138 | $6.03 | $24,952.14 | 783,590 | |
| 12/29/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 8,096 | $5.95 | $48,171.20 | 787,728 | |
| 12/26/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 3,350 | $6.32 | $21,172.00 | 795,824 | |
| 12/24/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 1,490 | $6.27 | $9,342.30 | 799,174 | |
| 12/23/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 6,831 | $6.27 | $42,830.37 | 800,664 | |
| 12/22/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 4,367 | $6.54 | $28,560.18 | 383,201 | |
| 12/19/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 5,582 | $6.45 | $36,003.90 | 387,568 | |
| 12/18/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 5,816 | $6.33 | $36,815.28 | 393,150 | |
| 12/17/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 2,884 | $6.61 | $19,063.24 | 398,966 | |
| 12/16/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 7,030 | $6.31 | $44,359.30 | 401,850 | |
| 12/15/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 10,580 | $6.49 | $68,664.20 | 408,880 | |
| 12/12/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 7,603 | $6.79 | $51,624.37 | 419,460 | |
| 12/11/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 10,907 | $6.81 | $74,276.67 | 427,063 | |
| 12/10/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 9,921 | $6.42 | $63,692.82 | 437,970 | |
| 12/9/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 15,031 | $5.95 | $89,434.45 | 447,891 | |
| 12/8/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 21,463 | $5.70 | $122,339.10 | 462,922 | |
| 12/5/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 37,235 | $5.94 | $221,175.90 | 484,385 | |
| 12/4/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 72,748 | $6.73 | $489,594.04 | 521,620 | |
| 12/3/2025 | Chidozie Ugwumba | Major Shareholder | Sell | 56,577 | $7.86 | $444,695.22 | 594,368 | |
| 8/21/2025 | General Resonance Llc | Major Shareholder | Sell | 3,401 | $5.34 | $18,161.34 | 704,591 | |
| 5/27/2025 | General Resonance Llc | Major Shareholder | Sell | 420 | $2.45 | $1,029.00 | 710,432 | |
| 3/18/2025 | General Resonance Llc | Major Shareholder | Sell | 1,333 | $4.45 | $5,931.85 | 712,252 | |
| 9/30/2024 | David J Matlin | Director | Buy | 92,307 | $4.75 | $438,458.25 | 444,491 | |
| 9/30/2024 | Mark Mortenson | Insider | Buy | 20,512 | $4.75 | $97,432.00 | 28,949 | |
| 4/30/2024 | General Resonance Llc | Major Shareholder | Sell | 650 | $8.40 | $5,460.00 | 766,335 | |
| 4/24/2024 | General Resonance Llc | Major Shareholder | Sell | 500 | $6.60 | $3,300.00 | 767,485 | |
| 4/9/2024 | General Resonance Llc | Major Shareholder | Sell | 1,125 | $7.80 | $8,775.00 | 771,410 | |
| 11/10/2023 | David J Matlin | Director | Buy | 12,500 | $8.20 | $102,500.00 | 352,184 | |
| 6/26/2023 | John Henry Stevens | Director | Buy | 15,822 | $16.00 | $253,152.00 | 40,010 | |
| 6/26/2023 | Robert Dee Etherington | CEO | Buy | 1,250 | $16.20 | $20,250.00 | 1,250 | |
| 6/16/2023 | David J Matlin | Director | Buy | 75,000 | $16.00 | $1,200,000.00 | 339,684 | |
Clene Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/13/2025 | Scoggin Management LP | 250,000 | $1.51M | 0.2% | +75.1% | 2.483% |  |
| 11/12/2025 | Lunt Capital Management Inc. | 52,260 | $0.32M | 0.1% | +2.5% | 0.519% |  |
| 11/4/2025 | Jones Financial Companies Lllp | 5,000 | $29K | 0.0% | N/A | 0.050% |  |
| 8/15/2025 | Scoggin Management LP | 142,750 | $0.56M | 0.1% | +42.8% | 1.726% |  |
| 8/14/2025 | Jane Street Group LLC | 12,095 | $47K | 0.0% | N/A | 0.146% |  |
| 7/28/2025 | Lunt Capital Management Inc. | 51,010 | $0.20M | 0.1% | +71.2% | 0.617% |  |
| 4/23/2025 | Penn Davis Mcfarland Inc. | 11,000 | $34K | 0.0% | N/A | 0.128% |  |
| 2/17/2025 | Fullcircle Wealth LLC | 13,023 | $69K | 0.0% | N/A | 0.156% |  |
| 2/13/2025 | Renaissance Technologies LLC | 18,040 | $96K | 0.0% | N/A | 0.217% |  |
| 2/12/2025 | Geode Capital Management LLC | 65,112 | $0.35M | 0.0% | +52.9% | 0.782% |  |
| 2/6/2025 | SBI Securities Co. Ltd. | 13,025 | $69K | 0.0% | N/A | 0.158% |  |
| 1/22/2025 | Parsons Capital Management Inc. RI | 36,500 | $0.19M | 0.0% | N/A | 0.437% |  |
| 10/24/2024 | Lunt Capital Management Inc. | 29,540 | $0.14M | 0.1% | -95.0% | 0.431% |  |
| 10/21/2024 | Castleview Partners LLC | 12,783 | $59K | 0.0% | N/A | 0.186% |  |
| 7/10/2024 | Csenge Advisory Group | 269,600 | $96K | 0.0% | +131.2% | 0.210% |  |
| 1/26/2024 | Soltis Investment Advisors LLC | 109,517 | $32K | 0.0% | -50.0% | 0.085% |  |
| 11/15/2023 | Worth Venture Partners LLC | 1,404,284 | $0.70M | 0.4% | -5.3% | 1.094% |  |
| 11/15/2023 | Kepos Capital LP | 131,322 | $65K | 0.0% | -22.8% | 0.102% |  |
| 11/13/2023 | Silverarc Capital Management LLC | 500,000 | $0.25M | 0.1% | +100.0% | 0.389% |  |
| 11/13/2023 | AIGH Capital Management LLC | 5,801,878 | $2.88M | 1.4% | -2.3% | 4.518% |  |
| 11/8/2023 | Vivo Capital LLC | 2,645,338 | $1.40M | 0.2% | -41.5% | 2.060% |  |
| 11/1/2023 | Csenge Advisory Group | 116,600 | $58K | 0.0% | N/A | 0.091% |  |
| 10/11/2023 | AE Wealth Management LLC | 172,528 | $86K | 0.0% | +208.5% | 0.134% |  |
| 8/15/2023 | Silverarc Capital Management LLC | 250,000 | $0.22M | 0.1% | N/A | 0.319% |  |
| 8/11/2023 | AWM Investment Company Inc. | 5,000,000 | $4.40M | 0.6% | N/A | 6.378% |  |
| 7/17/2023 | Impact Partnership Wealth LLC | 55,928 | $49K | 0.0% | N/A | 0.071% |  |
| 7/10/2023 | AE Wealth Management LLC | 55,928 | $49K | 0.0% | N/A | 0.071% |  |
| 5/10/2023 | Condor Capital Management | 165,836 | $0.19M | 0.0% | N/A | 0.214% |  |
| 2/13/2023 | Kepos Capital LP | 344,427 | $0.34M | 0.0% | -13.9% | 0.467% |  |
| 11/15/2022 | Tang Capital Management LLC | 1,100,000 | $3.08M | 0.4% | N/A | 1.490% |  |
| 11/15/2022 | Kepos Capital LP | 400,000 | $1.12M | 0.1% | -33.3% | 0.542% |  |
| 10/21/2022 | Morgan Jess S & Co. Inc. | 112,000 | $0.31M | 0.3% | +28.4% | 0.176% |  |
| 8/12/2022 | Ikarian Capital LLC | 70,000 | $0.18M | 0.0% | -86.4% | 0.111% |  |
| 8/8/2022 | Oppenheimer & Co. Inc. | 32,026 | $81K | 0.0% | +27.2% | 0.051% |  |
| 5/16/2022 | Morgan Jess S & Co. Inc. | 87,250 | $0.34M | 0.3% | +193.3% | 0.138% |  |
| 5/11/2022 | Veritable L.P. | 20,000 | $79K | 0.0% | N/A | 0.032% |  |
| 5/9/2022 | Mitsubishi UFJ Kokusai Asset Management Co. Ltd. | 241,737 | $0.95M | 0.0% | -3.4% | 0.382% |  |
| 5/2/2022 | Allspring Global Investments Holdings LLC | 32,129 | $0.13M | 0.0% | N/A | 0.051% |  |
| 2/7/2022 | Mitsubishi UFJ Kokusai Asset Management Co. Ltd. | 250,235 | $1.11M | 0.0% | N/A | 0.402% |  |
| 2/2/2022 | Oppenheimer & Co. Inc. | 22,214 | $91K | 0.0% | N/A | 0.036% |  |
| 11/15/2021 | Penserra Capital Management LLC | 5,154 | $35K | 0.0% | -35.9% | 0.008% |  |
| 11/12/2021 | Geode Capital Management LLC | 405,737 | $2.77M | 0.0% | +0.8% | 0.660% |  |
| 11/9/2021 | BlackRock Inc. | 1,065,726 | $7.28M | 0.0% | -9.5% | 1.733% |  |
| 11/4/2021 | Deutsche Bank AG | 11,284 | $77K | 0.0% | -16.9% | 0.018% |  |
Data available starting January 2016
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Read More on Clene
Volume
93,226 shs
Average Volume
122,167 shs
Market Capitalization
$46.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.81
Who are the company insiders with the largest holdings of Clene?